CORZIDE (Nadolol and Bendroflumethiazide Tablets) is indicated in the management of hypertension.

This fixed combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual may be more convenient than the separate components.

DOSAGE MUST BE INDIVIDUALIZED (SEE INDICATIONS). CORZIDE MAY BE ADMINISTERED WITHOUT REGARD TO MEALS.

Bendroflumethiazide is usually given at a dose of 5 mg daily. The usual initial dose of nadolol is 40 mg once daily whether used alone or in combination with a diuretic. Bendroflumethiazide in CORZIDE is 30 percent more bioavailable than that of 5 mg Naturetin tablets. Conversion disease. from 5 mg NATURETIN to CORZIDE represents a 30 percent increase in dose of bendroflumethiazide.

The initial dose of CORZIDE (Nadolol and Bendroflumethiazide Tablets) may therefore be the 40 mg/5 mg tablet once daily. When the antihypertensive response is not satisfactory, the dose may be increased by administering the 80 mg/5 mg tablet once daily.

When necessary, another antihypertensive agent may be added gradually beginning with 50 percent of the usual recommended starting dose to avoid an excessive fall in blood pressure.

Dosage Adjustment in Renal Failure†Absorbed nadolol is excreted principally by the kidneys and, although nonrenal elimination does occur, dosage adjustments are necessary in patients with renal impairment. The following dose intervals are recommended:

CORZIDE (Nadolol and Bendroflumethiazide Tablets)

† 40 mg nadolol combined with 5 mg bendroflumethi-azide in bottles of 100 tablets (NDC 61570-175-01).

† 80 mg nadolol combined with 5 mg bendroflumethi-azide in bottles of 100 tablets (NDC 61570-176-01).

Round, biconvex tablets are white to bluish white with dark blue specks. Each tablet has a full bisect bar. Tablet identification numbers: 40 mg/5 mg combination, 283; 80 mg/5 mg combination, 284.

Keep bottle tightly closed. Store at room temperature; avoid excessive heat.

Distributed by: Monarch Pharmaceuticals, Inc., Bristol, TN 37620 Manufactured by: Bristol-Myers Squibb Company, Princeton, NJ 08543 USA

Revised October 2001

Bookmark this page: